Advertisement

Chronic Inflammatory Demyelinating Polyneuropathy

  • Miki SuzukiEmail author
  • Gérard Said
Chapter
Part of the Contemporary Clinical Neuroscience book series (CCNE)

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease that targets the myelin sheaths of peripheral nerves. Lacking a specific diagnostic test, CIDP is diagnosed on the basis of the clinical presentation and demonstration of demyelination by electrodiagnostic or nerve biopsy studies. There are many phenotype variants of CIDP. Typical CIDP involves motor and sensory nerve dysfunction, with motor deficits reported in up to 94% of patients and sensory deficits in up to 89%. Half to two-thirds of patients with CIDP display the typical phenotype. The three proven treatments for CIDP are intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange. In the last years, a set of autoantibodies against proteins located at the node of Ranvier has been identified in some patients with CIDP. IVIG treatment is not satisfactory in the majority of antibody-positive CIDP patients.

Keywords

Chronic inflammatory demyelinating polyneuropathy Intravenous immunoglobulin Steroid Paranode Nerve biopsy 

References

  1. 1.
    Harris W, Newcomb WD. A case of relapsing interstitial hypertrophic polyneuritis. Brain. 1929;52:108–16.CrossRefGoogle Scholar
  2. 2.
    Austin JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and predvisone. Brain. 1958;81:157–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975;50:621–37.PubMedGoogle Scholar
  4. 4.
    Prineas JW, McLeod JG. Chronic relapsing polyneritis. J Neurol Sci. 1976;27:427–58.PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas PK, Lascelles RG, Hallpike JF, Hewer RL. Recurrent and chronic relapsing Guillain-Barre polyneuritis. Brain. 1969;92:589–606.PubMedCrossRefGoogle Scholar
  6. 6.
    Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in Southeast England. Eur J Neurol. 2014;21:28–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39:432–8.PubMedCrossRefGoogle Scholar
  8. 8.
    McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol. 1999;46:910–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Iijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry. 2008;79:1040–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Chia L, Fernandez A, Lacroix C, Adams D, Planté V, Said G. Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients. Brain. 1996;119:1091–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Suzuki M, Lacroix C, Lozeron P, Said G. Clinical features of neuropathy over 80 years: a retrospective study of 100 patients. J Neurol. 2006;253(Suppl 2):1185–6.Google Scholar
  12. 12.
    Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:617–8.CrossRefGoogle Scholar
  13. 13.
    McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain. 1987;110:1617–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Maisonobe T, Chassande B, Vérin M, Jouni M, Léger JM, Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neruosurg Psychiatry. 1996;61:36–42.CrossRefGoogle Scholar
  15. 15.
    Bouchcard C, Lacroix C, Planté V, Adams D, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52:498–503.CrossRefGoogle Scholar
  16. 16.
    Sapperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311–24.CrossRefGoogle Scholar
  17. 17.
    Dyck PJ, Tracy JA. History, diagnosis and management of chronic inflammatory demyelinating polyneuropathy. Mayo Clin Proc. 2018;93:777–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Hahn AF, Hartung HP, Dyck PJ. Chronic inflammatory demyelinating polyneuropathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, vol. 2. 4th ed. Philadelphia: Elsevier/Saunders; 2005. p. 2221–53.CrossRefGoogle Scholar
  19. 19.
    Said G, Saimot AG, Lacroix C. Neurological complication of HIV and AIDS. In: Warlow CP, van Giin J, editors. Major problems in neurology. London: W.B. Saunders; 1997. p. 1–24.Google Scholar
  20. 20.
    Notermans NC, Wokke JH, Franssen H, van der Graaf Y, Vermeulen M, van den Berg LH, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry. 1993;56:1066–71.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    McMillan HJ, Kang PB, Jones HR, Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord. 2013;23:103–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Sladky JT, Brown MJ, Berman PH. Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid-responsive disorder. Ann Neurol. 1986;20:76–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878–84.PubMedCrossRefGoogle Scholar
  24. 24.
    Figueroa JJ, Dyck PJ, Laughlin RS, Mercado JA, Massie R, Sandroni P, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2012;78:702–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal inflammatory demyelinating polyneuropathy. Muscle Nerve. 1999;22:758–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982;32:958–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J Peripher Nerv Syst. 1997;2:362–9.PubMedGoogle Scholar
  28. 28.
    Misra VP, Walker RW. Acute-onset painful upper limb multifocal demyelinating motor neuropathy. J Neurol. 2000;247:949–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992;55:677–80.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    van Dijk GW, Netermans NC, Franssen H, Wokke JH. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol. 1999;246:1134–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Ohkoshi N, Harada K, Nagata H, Yato M, Shoji S. Ataxic form of chronic inflammatory demyelinating polyneuropathy: clinical features and pathological study of the sural nerves. Eur Neurol. 2001;45:241–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Chin RL, Latov N, Sander HW, Hays AP, Croul SE, Magda P, et al. Sensory CIDP presenting as cry ng polyneuropathy: a study of 28 cases with nerve biopsy. J Neurol. 2003; 250 (Suppl 2):1; Ptogenic sensory polyneuropathy. J Peripher Nerv Syst. 2004; 9:132–7.Google Scholar
  33. 33.
    Ferreira A, Lozeron P, Lacroix C, Adams D, Said G. Sensory chronic inflammatory demyelinating polyneuropathies. J Neurol. 2003;250(Suppl 2):147.Google Scholar
  34. 34.
    Lozeron P, Ferreira A, Lacroix C, Adams D, Said G. Electrophysiological findings in clinical pure sensory chronic demyelinating polyneuropathies. J Neurol. 2003;250(Suppl 2):68.Google Scholar
  35. 35.
    Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possible treatable sensory ataxia. Neurology. 2004;63:1662–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615–20.PubMedCrossRefGoogle Scholar
  37. 37.
    Miescher GC, Latov N, Steack AJ. Dysglobulinemic neuropathies. In: Antel J, Birnbaum G, Hartung HP, editors. Clinical immunology. London: Blackwell Science; 1998. p. 307–15.Google Scholar
  38. 38.
    Sabatelli M, Madia F, Mignogna T, Lippi G, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001;248:772–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical feature of 102 patients. J Neurol. 2003;250:714–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics. 1999;30:190–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Nevo Y, Pestronk A, Kornberg AJ, Connolly AM, Yee WC, Iqbal I, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996;47:98–102.PubMedCrossRefGoogle Scholar
  42. 42.
    Hattori N, Misu K, Koike H, Ichimura M, Nagamatsu M, Hirayama M, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001;15:57–63.CrossRefGoogle Scholar
  43. 43.
    Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul Disord. 2000;10:398–406.PubMedCrossRefGoogle Scholar
  44. 44.
    Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve. 1997;20:1569–75.PubMedCrossRefGoogle Scholar
  45. 45.
    Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci. 1996;142:59–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2000;23:37–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Lozeron P, Nahum L, Lacroix C, Ropert A, Guglielmi JM, Said G. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol. 2002;249:569–75.PubMedCrossRefGoogle Scholar
  48. 48.
    Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. Demyelinating neuropathy in diabetes mellitus. Arch Neurol. 2002;59:758–65.PubMedCrossRefGoogle Scholar
  49. 49.
    Laughlin RS, Dyck PJ, Melton LJ 3rd, Lerbson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73:39–45.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Said G, Bathien N, Cesaro P. Peripheral neuropathies and tremor. Neurology. 1982;32:480–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Thomas PK, Walker RW, Rudge P, Morgan-Hughes JA, King RH, Jacobs JM, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain. 1987;110:53–76.PubMedCrossRefGoogle Scholar
  52. 52.
    Mills KR, Murray NM. Neurophysiological evaluation of associated demyelinating peripheral neuropathy and multiple sclerosis: a case report. J Neurol Neurosurg Psychiatry. 1986;49:320–3.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Di Trapani G, Carnevale A, Cioffi RP, Massaro AR, Profice P. Multiple sclerosis associated with peripheral demyelinating neuropathy. Clin Neuropathol. 1996;15:135–8.PubMedGoogle Scholar
  54. 54.
    Vural A, Doppler K, Meinl E. Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol. 2018;9:1129.  https://doi.org/10.3389/fimmu.2018.01029.CrossRefGoogle Scholar
  55. 55.
    Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–77.PubMedCrossRefGoogle Scholar
  56. 56.
    Van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991;48:217–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Hattori N, Misu K, Koike H, Ichimura M, Nagamatsu M, Hirayama M, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001;184:57–63.PubMedCrossRefGoogle Scholar
  58. 58.
    Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry. 2006;77:66–70.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Dalakas MC. Advance in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;16:507–17.CrossRefGoogle Scholar
  60. 60.
    Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973–85.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Schmit B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve. 1996;19:474–87.CrossRefGoogle Scholar
  62. 62.
    Misawa S, Kuwabara S, Mori M, Kawaguchi N, Yoshiyama Y, Hattori T. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology. 2001;56:666–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci. 1999;163:47–52.PubMedCrossRefGoogle Scholar
  64. 64.
    Pollard JD. Chronic inflammatory demyelinating polyradiculoneuropathy. In: McLeod J, editor. Inflammatory neuropathies: Bailliere’s clinical neurology, vol. 3. London: WB Saunders; 1994. p. 107–27.Google Scholar
  65. 65.
    Kiefer R, Kiesseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nerve system. Prog Neurobiol. 2001;64:109–27.PubMedCrossRefGoogle Scholar
  66. 66.
    Mausberg AK, Dorok M, Stettner M, Muller M, Hartung HP, Dehmel T, et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology. 2013;80:296–303.PubMedCrossRefGoogle Scholar
  67. 67.
    Melendez-Vasquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, et al. Immunological investigation of chronic inflammatory demyelinating polyraduculoneuropathy. J Neuroimmunol. 1997;73:124–34.PubMedCrossRefGoogle Scholar
  68. 68.
    Yuki N, Tagawa Y, Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1996;70:1–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol. 2000;104:139–46.PubMedCrossRefGoogle Scholar
  70. 70.
    Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol. 2000;47:765–75.PubMedCrossRefGoogle Scholar
  71. 71.
    Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RA. Antibody responses to P0 and P2 myelin proteins in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol. 1993;46:245–51.PubMedCrossRefGoogle Scholar
  72. 72.
    Inglis HR, Csurhes PA, McCombe PA. Antibody responses to patients of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:419–22.PubMedCrossRefGoogle Scholar
  73. 73.
    Kwa MS, van Shchaik IN, Brand A, Baas F, Vermeulen M. Investigation of serum response to PMP22, connexin 32 and P0 in inflammatory neuropathies. J Neuroimmunol. 2001;116:220–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Querol L, Deveax J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13:533–47.PubMedCrossRefGoogle Scholar
  75. 75.
    Illa I. ARTHUR ASBURY LECTURE: chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. J Peripher Nerv Syst. 2017;22:418–24.PubMedCrossRefGoogle Scholar
  76. 76.
    Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 2014;10:435–46.PubMedCrossRefGoogle Scholar
  77. 77.
    European Federation of Neurological Societies/. Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst. 2010;15:1–9.Google Scholar
  78. 78.
    Hughes RA. Chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:281–2.PubMedCrossRefGoogle Scholar
  79. 79.
    Bromberg MB. Review of the evolution of electrodiagnositc criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2011;43:780–94.PubMedCrossRefGoogle Scholar
  80. 80.
    Nicolas G, Maisonobe T, Le Forestoer N, Léger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002;25:26–30.PubMedCrossRefGoogle Scholar
  81. 81.
    Isose S, Kuwabara S, Kokubun N, Sato Y, Mori M, Shibuya K, et al. Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst. 2009;14:151–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Kuwabara S, Ogawara K, Misawa S, Mori M, Hattori T. Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2002;72:37–42.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Ruts L, Drenthen J, Jacobs BC, van Doom PA. Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;25:1680–6.CrossRefGoogle Scholar
  84. 84.
    Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989;12:435–51.PubMedCrossRefGoogle Scholar
  85. 85.
    Ho TW, Li CY, Comblath DR, Gao CY, Asbury AK, Griffin JW, et al. Patterns of recovery in the Guillain-Barre syndromes. Neurology. 1997;48:695–700.PubMedCrossRefGoogle Scholar
  86. 86.
    Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.PubMedCrossRefGoogle Scholar
  87. 87.
    Bragg JA, Benatar MG. Sensory nerve conduction slowing is a specific marker for CIDP. Muscle Nerve. 2008;38:1599–603.PubMedCrossRefGoogle Scholar
  88. 88.
    Krarup C, Trojaborg W. Sensory pathophysiology in chronic acquired demyelinating neuropathy. Brain. 1996;119:257–70.PubMedCrossRefGoogle Scholar
  89. 89.
    Bromberg MB, Albers JW. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve. 1993;16:262–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Yiannikas C, Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve. 2008;38:1447–54.PubMedCrossRefGoogle Scholar
  91. 91.
    Fuglsang-Frederiksen A, Pugdahl K. Current status on electrodiagnostic standards and guidelines in neuromuscular disorders. Clin Neurophysiol. 2011;122:440–55.PubMedCrossRefGoogle Scholar
  92. 92.
    Sander HW, Latov N. Research criteria for defining patients with CIDP. Neurology. 2003;60(Suppl 3):8–15.CrossRefGoogle Scholar
  93. 93.
    Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology. 1982;32:592–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Van den Bergh PYK, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29:565–74.PubMedCrossRefGoogle Scholar
  95. 95.
    Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85:498–504.PubMedCrossRefGoogle Scholar
  96. 96.
    Haq RU, Fries TJ, Pendlebury WW, Kenny MJ, Badger GJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Arch Neurol. 2000;57:1745–50.PubMedCrossRefGoogle Scholar
  97. 97.
    Latov N. Diagnosis of CIDP. Neurology. 2002;59:S2–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Vallet JM, Tabaraud F, Magy L, Torny F, Bernet-Bernady P, Macian F, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve. 2003;27:478–85.CrossRefGoogle Scholar
  99. 99.
    Allen JA, Ney J, Lewis RA. Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. Muscle Nerve. 2018;57:542–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Molenaar DS, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Nerrosurg Psychiatry. 1998;64:84–9.CrossRefGoogle Scholar
  101. 101.
    Bosboom WM, van den Berg LH, Franssen H, Giesbergen PC, Flach HZ, van Putten AM, et al. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain. 2001;124:2427–38.PubMedCrossRefGoogle Scholar
  102. 102.
    Van Es HW, van den Berg LH, Franssen H, Witkamp TD, Ramos LM, Notermans NC, et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology. 1997;48:1218–24.PubMedCrossRefGoogle Scholar
  103. 103.
    Duggins AJ, McLeod JG, Pollard JD, Davies L, Yang F, Thompson EO, et al. Brain. 1999;122:1383–90.PubMedCrossRefGoogle Scholar
  104. 104.
    Hiwatashi A, Togao O, Yamashita K, Kikuchi K, Ogata H, Yamasaki R, et al. Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). Eur Radiol. 2017;27:447–53.PubMedCrossRefGoogle Scholar
  105. 105.
    Ishikawa T, Asalura K, Mizutani Y, Ueda A, Murate K, Hikichi C, et al. MR neurography for the evaluation of CIDP. Muscle Nerve. 2017;55:483–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Zaidman CM, Al-Lozi M, Pestrouk A. Peripheral nerve size in normal and patients with polyneuropathy: an ultrasound study. Muscle Nerve. 2009;40:960–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Sugimoto T, Ochi K, Hosomi N, Takahashi T, Ueno H, Nakamura T, et al. Ultrasonographic nerve enlargement of the median an ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease: distinction from patients with chronic inflammatory demyelinating polyneuropathy. J Neurol. 2013;260:2580–7.PubMedCrossRefGoogle Scholar
  108. 108.
    Schneider C, Bucher F, Cursiefen C, Fink GR, Heihdl LM, Lehmann HC. Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2014;19:322–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, et al. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Ann Clin Transl Neurol. 2015;3:88–100.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Prineas JW. Pathology of inflammatory demyelinating neuropathies. Baillieres Clin Neurol. 1994;3:1–24.PubMedGoogle Scholar
  111. 111.
    Sommer C, Koch S, Lammens M, Gabreel-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65:1924–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Rizzuto N, Morbin M, Cavallaro T, Ferrari S, Fallahi M, Galiazzo-Rizzuto S. Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neuropathol. 1998;96:603–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Vital C, Vital A, Lagueny A, Ferrer X, Fontan D, Barat M, et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct Pathol. 2000;24:363–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Nagamatu M, Terao S, Misu K, Li M, Hattori N, Ichimura M, et al. Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1999;66:727–33.CrossRefGoogle Scholar
  115. 115.
    England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72:177–84.PubMedCrossRefGoogle Scholar
  116. 116.
    Oh SJ, LaGanke C, Powers R, Wolfe GI, Quinton RA, Burns DK. Multifocal motor sensory demyelinating neuropathy: inflammatory demyelinating polyradiculoneuropathy. Neurology. 2005;65:1639–42.PubMedCrossRefGoogle Scholar
  117. 117.
    Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, et al. Paraodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017;88:465–73.PubMedCrossRefGoogle Scholar
  118. 118.
    Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.PubMedCrossRefGoogle Scholar
  119. 119.
    Joint Task Force of EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society---first revision. J Peripher Nerv Syst. 2010;15:295–301.CrossRefGoogle Scholar
  120. 120.
    Hahn AF, Beydoun SR, Lawson V. IVIG in MMN Study Team, Oh M, Empson VG, et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Perpher Nerv Syst. 2013;18:321–30.CrossRefGoogle Scholar
  121. 121.
    Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778–83.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology. 1998;50:1480–2.PubMedCrossRefGoogle Scholar
  123. 123.
    Kelly JJ. Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance. Rev Neurol Dis. 2008;5:14–22.Google Scholar
  124. 124.
    Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018;11:1756285617746640.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Clit Rev Neurobiol. 1988;3:301–32.Google Scholar
  126. 126.
    Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain. 1994;117:941–7.PubMedCrossRefGoogle Scholar
  127. 127.
    Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Opt Neurol. 2010;12:71–83.CrossRefGoogle Scholar
  128. 128.
    Magy L, Kabore R, Mathis S, Lebeau P, Ghorab K, Caudie C, et al. Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J Immunol Res. 2015;2015:1.  https://doi.org/10.1155/2015/450391.CrossRefGoogle Scholar
  129. 129.
    Eurelings M, Notermans NC, Van de Donk N, Lokhorst HM. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve. 2001;24:1295–302.PubMedCrossRefGoogle Scholar
  130. 130.
    Bleasel AF, Hawke SH, Pollard JD, McLeod JG. IgG monoclonal paraproteinaemia and peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1993;56:52–7.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain. 1997;118:359–68.CrossRefGoogle Scholar
  132. 132.
    Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:814–29.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Keddie S, Lunn MP. POEMS syndrome. Curr Opin Neurol. 2018;31:551–8.PubMedGoogle Scholar
  134. 134.
    Nasu S, Misawa S, Sekiguchi Y, Shibuya K, Kanai K, Fujimaki Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinative polyneuropathy. J Neurol Neurosurg Psychiatry. 2012;83:476–9.PubMedCrossRefGoogle Scholar
  135. 135.
    Pranté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69:693–8.CrossRefGoogle Scholar
  136. 136.
    Planté-Bordeneuve V, Parman Y, Guiochon-Mantel A, Alj Y, Deymeer F, Serdaroglu P, et al. The range of chronic demyelinating polyneuropathy of infancy: a clinic-pathological and genetic study of 15 unrelated cases. J Neurol. 2001;248:795–803.PubMedCrossRefGoogle Scholar
  137. 137.
    Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH. Predonisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc. 1982;57:239–46.PubMedGoogle Scholar
  138. 138.
    Bird SJ, Sladsky JT. Corticosteroid-responsive dominantly inherited neuropathy in childhood. Neurology. 1991;41:437–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB, et al. Coexistent hereditary and inflammatory neuropathy. Brain. 2004;127:193–202.PubMedCrossRefGoogle Scholar
  140. 140.
    Dyck PJ, O’Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–41.PubMedCrossRefGoogle Scholar
  141. 141.
    Hughes RA. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol. 2008;7:136–44.PubMedCrossRefGoogle Scholar
  142. 142.
    Dyck P, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinationg polyradiculoneuropathy. Ann Neurol. 1994;36:838–45.PubMedCrossRefGoogle Scholar
  143. 143.
    Van Doorn PA. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol. 2004;17:607–13.PubMedCrossRefGoogle Scholar
  144. 144.
    Hughes RA. Randomized controlled trial of intravenous immunoglobulin versus oral predonisilone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.PubMedCrossRefGoogle Scholar
  145. 145.
    Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017:CD10369.  https://doi.org/10.1002/14651858.
  146. 146.
    Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN. PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012;78:1079–84.PubMedCrossRefGoogle Scholar
  147. 147.
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory disease with intravenous immunoglobulin. N Engl J Med. 2001;345:747–55.PubMedCrossRefGoogle Scholar
  148. 148.
    Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36–9.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209–12.PubMedCrossRefGoogle Scholar
  150. 150.
    Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–9.PubMedCrossRefGoogle Scholar
  151. 151.
    van Schail IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory in chronic inflammatory demyelinating polyneuropathy (PATH): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46.CrossRefGoogle Scholar
  152. 152.
    Vanhoutte EK, Latov N, Deng C, Hanna K, Houghes RAC, Bril V, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG and the ICE study. Eur J Neurol. 2013;20:748–55.PubMedCrossRefGoogle Scholar
  153. 153.
    Kuitwaard K, van Doorn PA. Newer therapeutic options for chronic inflammatory demyelinationg polyradiculoneuropathy. Drug. 2009;69:987–1001.CrossRefGoogle Scholar
  154. 154.
    Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of case in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146–60.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Mahdi-Rogers M, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids. Immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyneuropathy. Cochrane Database Syst Rev. 2013;(14):CD003280.Google Scholar
  156. 156.
    Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86:800–7.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of NeurologyTokyo Women’s Medical UniversityTokyoJapan
  2. 2.Institut Arthur VernesParisFrance

Personalised recommendations